RhumbLine Advisers
RKDA icon

RhumbLine Advisers’s Arcadia Biosciences RKDA Stock Holding History

RhumbLine Advisers’s Portfolio RKDA Stock Details RKDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-18
Closed -$40K – 3015
2016
Q1 		$40K Buy
18
+1
+6% +$2.13K ﹤0.01% 2971
2015
Q4 		$42K Buy
+17
New +$44.3K ﹤0.01% 3007

Other funds holding RKDA

WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
LRPA
L. Roy Papp & Associates Phoenix, Arizona $951M AUM 29.05% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
PP
Paloma Partners Greenwich, Connecticut $510M AUM 286.05% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

RhumbLine Advisers's RKDA Position: Q2 2016 in Review

RhumbLine Advisers sold out of Arcadia Biosciences (RKDA) in Q2 2016, closing a stake of 18 shares — an estimated $40K sold.

RhumbLine Advisers first reported a position in RKDA in Q4 2015 and held it in 2 quarters. The position peaked at $42K in Q4 2015. 20 funds tracked by Wall St. Rank hold RKDA as of Q2 2016.

  • RhumbLine Advisers reported no remaining Arcadia Biosciences position as of Q2 2016 after selling out during the quarter.
  • RhumbLine Advisers sold 18 Arcadia Biosciences shares in Q2 2016, an estimated $40K.
  • RhumbLine Advisers first reported a position in Arcadia Biosciences in Q4 2015 and held it in 2 quarters.
  • RhumbLine Advisers's Arcadia Biosciences position peaked at $42K in Q4 2015.
  • 20 funds tracked by Wall St. Rank held Arcadia Biosciences as of Q2 2016.

Based on RhumbLine Advisers's 13F filing for Q2 2016, filed 11 Aug 2016.